Join Growin Stock Community!

Bioxcel therapeutics, inc.BTAI.US Overview

US StockHealthcare
(No presentation for BTAI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BTAI AI Insights

BTAI Overall Performance

BTAI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BTAI Recent Performance

-1.50%

Bioxcel therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BTAI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BTAI Key Information

BTAI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BTAI Profile

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Price of BTAI

BTAI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BTAI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.12
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
48.57
PB Ratio
3.97
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-28.19%
Net Margin
-9070.61%
Revenue Growth (YoY)
-66.96%
Profit Growth (YoY)
-184.80%
3-Year Revenue Growth
-10.57%
3-Year Profit Growth
116.80%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.12
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
48.57
PB Ratio
3.97
Price-to-FCF
-
Gross Margin
-28.19%
Net Margin
-9070.61%
Revenue Growth (YoY)
-66.96%
Profit Growth (YoY)
-184.80%
3-Year Revenue Growth
-10.57%
3-Year Profit Growth
116.80%

  • When is BTAI's latest earnings report released?

    The most recent financial report for Bioxcel therapeutics, inc. (BTAI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BTAI's short-term business performance and financial health. For the latest updates on BTAI's earnings releases, visit this page regularly.

  • What is the operating profit of BTAI?

    According to the latest financial report, Bioxcel therapeutics, inc. (BTAI) reported an Operating Profit of -14.23M with an Operating Margin of -14,518.37% this period, representing a growth of 6.96% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BTAI's revenue growth?

    In the latest financial report, Bioxcel therapeutics, inc. (BTAI) announced revenue of 98K, with a Year-Over-Year growth rate of -54.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BTAI have?

    As of the end of the reporting period, Bioxcel therapeutics, inc. (BTAI) had total debt of 109.13M, with a debt ratio of 2.44. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BTAI have?

    At the end of the period, Bioxcel therapeutics, inc. (BTAI) held Total Cash and Cash Equivalents of 37.32M, accounting for 0.83 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BTAI go with three margins increasing?

    In the latest report, Bioxcel therapeutics, inc. (BTAI) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.8%%, operating margin of -14,518.37%%, and net margin of -31,541.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BTAI's profit trajectory and future growth potential.

  • Is BTAI's EPS continuing to grow?

    According to the past four quarterly reports, Bioxcel therapeutics, inc. (BTAI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BTAI?

    Bioxcel therapeutics, inc. (BTAI)'s Free Cash Flow (FCF) for the period is -18.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 14.99% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.